261 related articles for article (PubMed ID: 18948577)
21. SNX-2112, an Hsp90 inhibitor, induces apoptosis and autophagy via degradation of Hsp90 client proteins in human melanoma A-375 cells.
Liu KS; Liu H; Qi JH; Liu QY; Liu Z; Xia M; Xing GW; Wang SX; Wang YF
Cancer Lett; 2012 May; 318(2):180-8. PubMed ID: 22182451
[TBL] [Abstract][Full Text] [Related]
22. Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib.
Rice JW; Veal JM; Barabasz A; Foley B; Fadden P; Scott A; Huang K; Steed P; Hall S
Oncol Res; 2009; 18(5-6):229-42. PubMed ID: 20225761
[TBL] [Abstract][Full Text] [Related]
23. The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines.
McCleese JK; Bear MD; Fossey SL; Mihalek RM; Foley KP; Ying W; Barsoum J; London CA
Int J Cancer; 2009 Dec; 125(12):2792-801. PubMed ID: 19544563
[TBL] [Abstract][Full Text] [Related]
24. Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma.
Khong T; Spencer A
Mol Cancer Ther; 2011 Oct; 10(10):1909-17. PubMed ID: 21859842
[TBL] [Abstract][Full Text] [Related]
25. A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway.
Mao X; Cao B; Wood TE; Hurren R; Tong J; Wang X; Wang W; Li J; Jin Y; Sun W; Spagnuolo PA; MacLean N; Moran MF; Datti A; Wrana J; Batey RA; Schimmer AD
Blood; 2011 Feb; 117(6):1986-97. PubMed ID: 21135258
[TBL] [Abstract][Full Text] [Related]
26. Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization.
Han K; Xu X; Chen G; Zeng Y; Zhu J; Du X; Zhang Z; Cao B; Liu Z; Mao X
J Hematol Oncol; 2014 Jan; 7():9. PubMed ID: 24428908
[TBL] [Abstract][Full Text] [Related]
27. Antimyeloma activity of heat shock protein-90 inhibition.
Mitsiades CS; Mitsiades NS; McMullan CJ; Poulaki V; Kung AL; Davies FE; Morgan G; Akiyama M; Shringarpure R; Munshi NC; Richardson PG; Hideshima T; Chauhan D; Gu X; Bailey C; Joseph M; Libermann TA; Rosen NS; Anderson KC
Blood; 2006 Feb; 107(3):1092-100. PubMed ID: 16234364
[TBL] [Abstract][Full Text] [Related]
28. SNX-25a, a novel Hsp90 inhibitor, inhibited human cancer growth more potently than 17-AAG.
Wang S; Wang X; Du Z; Liu Y; Huang D; Zheng K; Liu K; Zhang Y; Zhong X; Wang Y
Biochem Biophys Res Commun; 2014 Jul; 450(1):73-80. PubMed ID: 24879994
[TBL] [Abstract][Full Text] [Related]
29. Bromo-honaucin A inhibits osteoclastogenic differentiation in RAW 264.7 cells via Akt and ERK signaling pathways.
Sapkota M; Li L; Choi H; Gerwick WH; Soh Y
Eur J Pharmacol; 2015 Dec; 769():100-9. PubMed ID: 26550952
[TBL] [Abstract][Full Text] [Related]
30. Induction of angiogenesis by heat shock protein 90 mediated by protein kinase Akt and endothelial nitric oxide synthase.
Sun J; Liao JK
Arterioscler Thromb Vasc Biol; 2004 Dec; 24(12):2238-44. PubMed ID: 15486309
[TBL] [Abstract][Full Text] [Related]
31. Rosiglitazone suppresses angiogenesis in multiple myeloma via downregulation of hypoxia-inducible factor-1α and insulin-like growth factor-1 mRNA expression.
Rui M; Huang Z; Liu Y; Wang Z; Liu R; Fu J; Huang H
Mol Med Rep; 2014 Oct; 10(4):2137-43. PubMed ID: 25050627
[TBL] [Abstract][Full Text] [Related]
32. Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation.
Koga F; Xu W; Karpova TS; McNally JG; Baron R; Neckers L
Proc Natl Acad Sci U S A; 2006 Jul; 103(30):11318-22. PubMed ID: 16844778
[TBL] [Abstract][Full Text] [Related]
33. Antiproliferative effect of HSP90 inhibitor Y306zh against pancreatic cancer is mediated by interruption of AKT and MAPK signaling pathways.
Xue N; Jin J; Liu D; Yan R; Zhang S; Yu X; Chen X
Curr Cancer Drug Targets; 2014; 14(7):671-83. PubMed ID: 25219422
[TBL] [Abstract][Full Text] [Related]
34. Transcriptomic and proteomic approach to studying SNX-2112-induced K562 cells apoptosis and anti-leukemia activity in K562-NOD/SCID mice.
Jin L; Xiao CL; Lu CH; Xia M; Xing GW; Xiong S; Liu QY; Liu H; Li YC; Ge F; Wang QD; He QY; Wang YF
FEBS Lett; 2009 Jun; 583(12):1859-66. PubMed ID: 19427857
[TBL] [Abstract][Full Text] [Related]
35. Anti-tumor activity of the HSP90 inhibitor SNX-2112 in pediatric cancer cell lines.
Chinn DC; Holland WS; Yoon JM; Zwerdling T; Mack PC
Pediatr Blood Cancer; 2012 Jun; 58(6):885-90. PubMed ID: 21796766
[TBL] [Abstract][Full Text] [Related]
36. Heat shock protein 90 inhibitor mycoepoxydiene modulates kinase signaling in cervical cancer cells and inhibits in-vivo tumor growth.
Lin P; Yi Y; Lu M; Wang M; Yang Y; Lu Y; Song S; Zheng Z; Deng X; Zhang L
Anticancer Drugs; 2015 Jan; 26(1):25-34. PubMed ID: 25014191
[TBL] [Abstract][Full Text] [Related]
37. Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922.
Wang CY; Guo ST; Wang JY; Yan XG; Farrelly M; Zhang YY; Liu F; Yari H; La T; Lei FX; Jin L; Zhang XD; Jiang CC
Oncotarget; 2016 Aug; 7(31):49597-49610. PubMed ID: 27391062
[TBL] [Abstract][Full Text] [Related]
38. The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma.
Breitkreutz I; Podar K; Figueroa-Vazquez V; Wilhelm S; Hayden PJ; Anderson KC; Raab MS
Ann Hematol; 2018 May; 97(5):839-849. PubMed ID: 29359239
[TBL] [Abstract][Full Text] [Related]
39. Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response.
Manni S; Brancalion A; Tubi LQ; Colpo A; Pavan L; Cabrelle A; Ave E; Zaffino F; Di Maira G; Ruzzene M; Adami F; Zambello R; Pitari MR; Tassone P; Pinna LA; Gurrieri C; Semenzato G; Piazza F
Clin Cancer Res; 2012 Apr; 18(7):1888-900. PubMed ID: 22351691
[TBL] [Abstract][Full Text] [Related]
40. Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling Adaptor DAP12.
Kameda Y; Takahata M; Komatsu M; Mikuni S; Hatakeyama S; Shimizu T; Angata T; Kinjo M; Minami A; Iwasaki N
J Bone Miner Res; 2013 Dec; 28(12):2463-75. PubMed ID: 23677868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
